Precision Medicine News and Research

RSS

Intellikine commences INK1117 Phase I dose escalation study in cancer

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.

12 Oct 2011

CU Cancer Center test identifies key biomarkers in advanced lung cancer

Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical trial.

12 Oct 2011

Asians struggling with alcoholism may benefit from naltrexone

New UCLA psychology research indicates that Asians who are struggling with alcoholism may benefit especially from naltrexone, one of three medications approved by the U.S. Food and Drug Administration for the treatment of alcoholism.

28 Sep 2011

John Theurer Cancer Center to join MMRF's Personalized Medicine Initiative

The John Theurer Cancer Center at Hackensack University Medical Center, a top 50 U.S. News best hospital for cancer, is one of the first four clinical sites enrolling patients in a landmark study designed to uncover the molecular segments and variations of multiple myeloma.

22 Sep 2011

Multispectral fluorescence imaging system can localize cancer cells during surgery

Ovarian cancer is one of the most frequent forms of cancer that affect women. As tumors can initially grow unchecked in the abdomen without causing any major symptoms, patients are usually diagnosed at an advanced stage and have to undergo surgery plus chemotherapy. During the operation, surgeons attempt to remove all tumor deposits as this leads to improved patient prognosis. To do this, however, they primarily have to rely on visual inspection and palpation - an enormous challenge especially in the case of small tumor nests or remaining tumor borders after the primary tumor excision.

20 Sep 2011

ESMO honors three medical oncologists for cancer care and research

The European Society for Medical Oncology (ESMO) has honored three of Europe's leading medical oncologists with prestigious awards recognizing their achievements in clinical care and research.

19 Sep 2011

Pathology Visions Conference to be held at Manchester Grand Hyatt in San Diego

Mahul B. Amin, MD, chair of the Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will offer his perspectives and expertise on personalized medicine and digital pathology at the 2011 Pathology Visions Conference.

3 Sep 2011

Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature.

3 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

CWRU, NeoProteomics sign licensing deal for four bioinformatics software programs

Case Western Reserve University and NeoProteomics Inc. have announced the university's licensing of four software programs designed to improve understanding of biology at a complex molecular level for improved treatment of cancers and various other diseases.

31 Aug 2011

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.

30 Aug 2011

New book on Health Informatics

University of Illinois professor Bruce Schatz, a faculty member at the Institute for Genomic Biology, has co-authored a groundbreaking book on Health Informatics, based on his popular computer science course.

30 Aug 2011

Lundbeck Canada makes landmark donation of $2.7M to support depression research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

Waters recognizes Head of TGen's Center for Proteomics for research excellence

Waters Corporation today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

First international conference on developmental, translational and clinical pharmacogenomics

The first international conference hosted by the University of South Florida College of Pharmacy will focus on ways to improve health care by customizing drug prescribing and treatment based on an individual's genetic makeup.

24 Aug 2011

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

The latest developments in molecular diagnostics, personalized medicine, and genetics testing will be featured topics when more than 1,000 pathologists gather at the Gaylord Texan on September 11 – 14 for the annual scientific meeting of the College of American Pathologists.

24 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011